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The Aging Heart and
Post-Infarction Left Ventricular Remodeling
Henry Shih, BA, Brian Lee, BA, Randall J. Lee, MD, PHD, Andrew J. Boyle, MBBS, PHD
San Francisco, California
Aging is a risk factor for heart failure, which is a leading cause of death world-wide. Elderly patients are more
likely than young patients to experience a myocardial infarction (MI) and are more likely to develop heart failure
following MI. The poor clinical outcome of aging in cardiovascular disease is recapitulated on the cellular level.
Increase in stress exposure and shifts in signaling pathways with age change the biology of cardiomyocytes. The
progressive accumulation of metabolic waste and damaged organelles in cardiomyocytes blocks the intracellular
recycling process of autophagy and increases the cell’s propensity toward apoptosis. Additionally, the decreased
cardiomyocyte renewal capacity in the elderly, due to reduction in cellular division and impaired stem cell func-
tion, leads to further cardiac dysfunction and maladaptive responses to disease or stress. We review the cellular
and molecular aspects of post-infarction remodeling in the aged heart, and relate them to the clinical problem
of post-infarction remodeling in elderly patients. (J Am Coll Cardiol 2011;57:9–17) © 2011 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.08.623p
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oyocardial Infarction (MI), Left Ventricular (LV)
emodeling, and Heart Failure
n the U.S., chronic heart failure (CHF) affects approxi-
ately 5.7 million people (1), and has been implicated as an
nderlying or contributing cause of death in 282,000 indi-
iduals per year at an estimated cost of $39 billion annually
2).
MI is one of the most common causes of CHF (2). The
ay in which MI leads to heart failure is a complex
ultifactorial process known as LV remodeling. MI, caused
y occlusion of an epicardial coronary artery, leads within
ours to irreversible death of the cardiomyocytes in the
istribution supplied by that artery. MI also initiates a
ascade of neurohormonal changes that attempt to compen-
ate for the lack of contractile function caused by the MI.
his initially maintains cardiac output and perfusion to the
ital organs, but with time, these compensatory mechanisms
ail, and there is progressive deterioration of cardiac func-
ion. The end result is a dilated, poorly functioning ventri-
le, and the clinical syndrome of heart failure ensues (3). At
he organ level, important pathological features of post-
nfarction LV remodeling include infarct expansion, myo-
ardial hypertrophy, cardiac fibrosis, and global ventricular
ilation (3). However, at the cellular level, the precise
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ccepted August 24, 2010.athophysiological changes associated with LV remodeling
emain incompletely characterized. Several molecular and
ellular processes appear to be particularly important, in-
luding ongoing apoptosis of cardiac myocytes, particularly
t the border zone of the MI, dysfunctional cardiomyocyte
utophagy, and reduction in the proliferative capacity of
ew cardiomyocytes. This ongoing cell loss and inability to
eplace lost cells may contribute to the deterioration in
ardiac function (Fig. 1). These cardiac changes are partic-
larly pronounced in the elderly. As our population ages (4),
he burden of heart failure is likely to increase. Developing
argeted therapies for post-infarction heart failure in the
lderly will require investigation into the specific pathophys-
ological changes of LV remodeling in this age group.
pidemiology of MI and Heart Failure With Aging
ging and MI. The incidence of MI increases dramatically
ith age. In the Framingham Heart Study, the incidence of
I more than doubles for men and increases more than
-fold in women from the age group of 55 to 64 years to the
ge group of 85 to 94 years (5). This increased incidence
ith age is also seen in the ARIC (Atherosclerosis Risk in
ommunities) surveillance study (5) (Fig. 2). Elderly pa-
ients are not only more likely than young patients to
xperience an MI, but are more likely to die from their MI.
he GISSI-2 (Gruppo Italiano per lo Studio della Soprav-
ivenza nell’Infarto Miocardico-2) study of thrombolysis for
eperfusion of first MI demonstrated an increase in the rate
f cardiac rupture with age, as well as an increase in both
n-hospital and post-discharge mortality rates with increas-
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Aging and Post-Infarct Remodeling December 28, 2010/January 4, 2011:9–17ing age. In this study, each year
of age was associated with a 6%
increase in mortality (6). Older
patients have a higher likelihood
of cardiac arrest following MI (7)
and are more likely to develop
mechanical complications of MI,
including papillary muscle rupture,
LV free wall rupture, and acquired
ventricular septal defect (8).
During MI, prompt reperfu-
sion of the infarct-related artery
is critical to prevent infarct ex-
pansion. Several large random-
ized controlled clinical trials have
hown that timely reperfusion with thrombolysis (9,10) or
ercutaneous coronary intervention (PCI) (11) limits the
xtent of myocardial necrosis, and decreases acute and
ong-term mortality. However, elderly patients are under-
epresented in clinical trials and real-world registries of
eperfusion therapies for MI (12,13). This may be for
everal reasons. First, elderly patients are at higher risk for
rocedural complications from PCI (14), and operators may
e less inclined to perform PCI on older patients, particu-
arly in the era of public reporting of figures. Second, there
s ongoing debate about whether these therapies are effective
n older persons (15,16). Third, older patients often present
ith atypical or no symptoms, or with left bundle branch
lock rather than ST-segment elevation on electrocardio-
ram (ECG) (12), thus delaying time to diagnosis and
reatment. Finally, the decision not to treat older patients
ay be based on physicians’ perception of bleeding risk (13),
r just therapeutic nihilism about the long-term prognosis
f elderly patients. However, a randomized controlled trial
f PCI versus fibrinolysis in elderly patients appeared to
how a benefit of PCI (17), and in elderly patients with
ardiogenic shock, there appears to be benefit in PCI
18,19).
ging and CHF. The prevalence of CHF increases with
ge. It rises from 1.9% of men and 1.4% of women at ages
0 to 59 years, to 14.7% of men and 12.8% of women over
he age of 80 years (2). Precise causes for the increased
Figure 1 Post-MI Remodeling of
the Heart at Cellular and Organ Levels
CM  cardiomyocyte; LV  left ventricular.
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
CHF  chronic heart failure
CPC  cardiac progenitor
cell
ECM  extracellular matrix
LV  left ventricle/
ventricular
MI  myocardial infarction
PCI  percutaneous
coronary interventiontncidence of heart failure in the elderly remain unknown.
any risk factors for developing CHF, such as diabetes and
ypertension, are more prevalent in elderly populations and
ave been reviewed elsewhere (20,21). Despite this, MI
emains one of the leading causes of CHF in the U.S. (2).
lderly patients are not only more likely to experience MI,
hey are also more likely to develop heart failure as a
onsequence of their MI than younger patients (22). As
urvival from MI increases, the prevalence of heart failure in
hose patients who survive MI is also increasing (23). In our
ging population, the higher incidence of MI will translate
nto an increasing burden of post-infarction heart failure on
ur health care system. Therapies specifically designed to
imit ventricular remodeling in elderly populations and stem
he tide of increasing heart failure prevalence are needed.
ellular and Molecular Aspects
f Ventricular Remodeling
ost animal experiments of MI created by left anterior
escending coronary artery (LAD) ligation are performed in
oung adult or adolescent animals, rather than in middle-
ged or older animals. This is in direct contradiction to the
uman equivalent, where MI is a disease of older adults. In
mouse model of MI, older animals had dramatically worse
utcomes compared with young animals. Gould et al. (24)
erformed LAD ligation on young adult mice (2 months of
ge), middle-aged mice (10 to 12 months of age), and older
ice (14 months of age). They demonstrated an age-
ependent reduction in survival in the month following MI.
dditionally, the older mice demonstrated greater infarct
xpansion and septal hypertrophy following MI. Impor-
antly, the changes seen in the older mice could be improved
ith therapy, in this case, angiotensin-converting enzyme
nhibitor (ACE inhibitor) captopril. This highlights the fact
hat although older animals fare worse following MI than
Figure 2 Increased Rates of MI With Age
Incidence of myocardial infarction (MI) increases with age, and is higher in men
than in women. Data derived from ARIC (Atherosclerosis Risk in Communities)
surveillance (5).heir younger counterparts, this poor prognosis is able to be
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December 28, 2010/January 4, 2011:9–17 Aging and Post-Infarct Remodelinganipulated with pharmacologic therapies. Therefore, more
esearch into the cellular and molecular events following MI
n the elderly may lead to more effective therapies for older
atients who suffer an MI.
ardiomyocyte apoptosis. Apoptosis is an evolutionarily
onserved and highly regulated mechanism that results in
he death and organized removal of unnecessary or malfunc-
ioning cells. Morphologically, the process is characterized
y regulated cellular shrinkage, chromatin condensation,
NA fragmentation, endocytosis of the dead cell by neigh-
oring cells with no spillage of intracellular content nor
nflammatory response (25). Cells undergo physiological
elf-induced death during the developmental process, and as
part of the renewal mechanism to maintain the balance in
he number of cells. Additionally, apoptosis is considered to
e an antitumor mechanism that keeps cells with DNA
amage from proliferating and thus preventing tumorgen-
sis (26). Aside from its physiological roles in development
nd homeostasis, apoptosis can also be activated in patho-
ogical states (Fig. 3).
For a long time, cardiomyocytes were considered long-
asting cells that do not self-renew. Analysis of cardiomyo-
yte apoptosis and the observation of cardiomyocyte hyper-
rophy following events of massive cell death support such
heory. At a basal rate of only 10  9 per 100,000 cells
0.01%) committed to programmed cell death at any time
27), it was presumed that the majority of cardiomyocytes
hare the same lifespan as the organism. In conditions such
s ischemic cardiomyopathy or idiopathic dilated cardiomy-
pathy, the reported extent of cardiomyocyte apoptosis
Figure 3 Aging of Cardiomyocytes
Aging is characterized with decreased cardiomyocyte renewal, possibly through the
cyte division. Additionally, changes in cardiomyocyte microenvironment and signali
of damaged protein and organelles in cardiomyoctyes blocks autophagy mechinary
satory neurohormonal signals induce the remaining cardiomyocytes to undergo hyp
oxidative damage. Regular arrows  promotion/induction; blocked arrows  inhibncreased to as much as 2% of cardiomyocyte nuclei being
poptotic at the time of the sample collection (27). Even
uring disease states, the level of cardiomyocyte apoptosis is
till low compared with other organs. The liver, for instance,
an sustain above 20% apoptosis in hepatocytes without
ethal consequence, and the difference is not due to the
ifference in time taken to complete apoptosis (28). The
recise cause for the basal rate of cardiomyocyte apoptosis in
he healthy heart is not understood; however, one can
peculate on various reasons. Normal cellular stress from
ay-to-day work may result in some specifically stressed
ells, whose gene expression shifts towards up-regulation of
ro-apoptotic profile and towards down-regulation of anti-
poptotic genes. Upon reaching a tipping point for apopto-
is, the cell falls into self-termination. Alternatively, sto-
hastic accumulation of mutation and errors in protein
ynthesis and accumulation of misfolded proteins can elicit
ndoplasmic reticulum stress response that results in acti-
ation of caspase cascade (29,30).
The effects of aging predispose cardiomyocytes to apop-
osis (31). Cardiomyocytes are exposed to oxidative damage
rom a high level of metabolism and mechanical stress from
onstant beating, and yet the low turnover rate requires the
ajority of them to survive through a human’s lifetime. At
he cellular level, the footprint of oxidative damaging in
ging leaves cardiomyocytes with a high level of disrupted
itochondria, lipofuscin, and other damaged organelles
32). In addition to the accumulation of somatic wear-and-
ear waste, aging cells and long-lived cells such as cardio-
yocytes are associated with increased nuclear and mito-
irment of both the stem cell differentiation into cardiomyoctyes and cardiomyo-
hways increase the cell’s propensity toward apoptosis. Progressive accumulation
re to clear out the intracellular waste can induce apoptosis of the cell. Compen-
hy and increase metabolic demand, thereby exposing the cellular contents to
lightning  detrimental effects of aging. Figure illustration by Craig Skaggs.impa
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Aging and Post-Infarct Remodeling December 28, 2010/January 4, 2011:9–17hondrial DNA damage (33). Together, these molecular
haracteristics can lead to an increase in pro-apoptotic gene
xpression profile across the heart. In fact, without the
resence of heart disease, an aging human heart on average
lready loses more than 30% of cardiomyocytes by
hronic loss of cells (34). Compounding an aging heart
ith the extra burden of cardiovascular disease leads to a
reater rate of cardiomyocyte loss (35) and worsens the
utcome of LV remodeling. Figure 4 demonstrates sev-
ral possible pathways affected by aging, whereby age may
nduce cardiomyocyte apoptosis (36–43).
utophagy. Autophagy, or self-eating, is a process in
hich the cell degrades its own components. Autophagy is
mechanism for the degradation of damaged long-lived
roteins and organelles, and is a survival response to
tarvation. Autophagy is essential for cardiomyocytes. The
ongevity of cardiomyocytes and their high energy require-
ents unavoidably expose the cell to a high level of
umulative oxidative damage and stress. Meanwhile, since
ost cardiomyocytes do not divide, halving cellular waste
hrough mitosis is not an option. Effective autophagy in
ardiomyocytes is therefore necessary to continue normal
etabolism and to maintain cellular survival. Autophagic
ailure is known to cause cardiomyopathy in experimental
Figure 4 Cardiomyocyte Apoptosis
Apoptosis can be mediated by the intrinsic or extrinsic pathways. Many factors as
toward apoptosis in the aging cardiomyocyte. Intrinsically, apoptosis is activated in
vation (36,37). These stressors activate cell death signaling chiefly through Bcl-2
Cytochrome C from mitochondria diffuses into the cytoplasm following the increas
downstream cascade to initiate caspase activities (38,39). Active caspases target
mentation factor-45 (ICAD/DEF45), and various other cytoplasmic proteins. Cleava
a DNase inhibitor, disinhibits DNase, thereby allowing it to break down DNA (41).
Binding of TNF-alpha or Fas ligand to their respective receptors activates TNF rece
teins (42,43). These proteins act on regulators of mitochondria to change the per
sic apoptosis activation on the caspase cascade. Figure illustration by Craig Skagnd clinical models. For instance, experimental disruption
f the autophagy gene atg5 in the heart causes an accumu-
ation of damaged proteins and leads to hypertrophy,
ubsequent dilated cardiomyopathy, and heart failure (44).
Although functional autophagy is crucial for normal
unctioning of cardiomyocytes, the effects of MI on autophagy,
nd conversely the effects of autophagy on the heart following
I, remain incompletely described. In hearts subjected to
eperfused MI, autophagy is activated first by the AMP
ctivated protein kinase (AMPK)-dependent mechanism dur-
ng the ischemic period, followed by Beclin-1–dependent
utophagy after reflow is established (45). In this model,
utophagy promotes the survival of cardiomyocytes during the
MPK-dependent (ischemic) phase, but becomes detrimental
uring the Beclin-1–dependent (reflow) phase.
Cardiomyocytes’ requirement for autophagy increases
ith age. Damage from reactive oxygen species impairs
unctional organelles, which then need to be cleared out by
utophagy in order to prevent cytotoxic effects. Such dam-
ge is especially pronounced with aging. For instance,
ong-term accumulation of oxidative damage results in
itochondria that are structurally disorganized, enlarged,
isabled for energy production, and prone to reactive oxygen
pecies leakage, posing oxidative damage for other cytosolic
d with these pathways are increased with aging, resulting in a predisposition
vent of hypoxia, oxidative stress, DNA damage, acidosis, or growth factor depri-
regulated increase of mitochondrial outer membrane permeabilization (MOMP).
itochondrial membrane permeability. In the cytosol, cytochrome C activates a
ar lamins, nuclear inhibitor of caspase-activated deoxyribonuclease/DNA frag-
nuclear lamins breaks down the nuclear structure (40). Cleavage of ICAD/DEF45,
ic apoptosis can be activated by Fas ligand or tumor necrosis factor (TNF)-alpha.
ssociated death domain (TRADD) and Fas-associated death domain (FADD) pro-
ity of the mitochondrial outer membrane, and this change converges with intrin-sociate
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December 28, 2010/January 4, 2011:9–17 Aging and Post-Infarct Remodelingroteins (46). Moreover, senescence-related damages, such
s mutation accumulation and protein aggregation, impair
itochondrial fission (47), which also serves as a waste-
learing mechanism by halving the amount of cytosolic
aste. Aging is also associated with reduced autophagy
fficiency (Fig. 5) (48,49). For instance, lipofusin, or pig-
ented waste from incomplete lysosomal digestion that
ccumulate in aging hearts, can disrupt lysosomal turnover.
ysosomes committed to degrading lipofusin are unable to
omplete the digestion, and therefore are also unavailable
or other uses (50), resulting in a net loss of intracellular
ysosomal availability and a bottleneck in autophagy flux.
ith autophagy impaired, biological waste such as reactive
xygen species can cause additional protein and organelle
amage. Impaired autophagy and the accumulation of toxic
iological waste together result in a vicious cycle leading to
efective cells.
ardiomyocyte hypertrophy. Classical paradigm holds
hat human cardiomyocytes proliferate only through the
evelopmental stages shortly after birth. The growth of the
eart in the later part of life is mediated chiefly through
ardiomyocyte hypertrophy, or increase in cell size (51).
nder the influence of hemodynamic load, neurohormonal
actors, or prohypertrophic signals, cardiomyocytes are ca-
able of significant growth in both transverse and longitu-
inal directions (52). Cardiomyocyte hypertrophy is pro-
ounced in an aging heart and contributes to the
evelopment of a dysfunctional heart (53). Clinically, hy-
ertrophy has been a strong predictor of morbidity and
Figure 5 Cardiomyocyte Autophagy
Autophagy may be triggered by the accumulation of intracellular protein aggregatio
with a highly regulated activation step that forms a double membrane autophagos
the lysosome, which contain proteases to digest the engulfed content. Aging incre
but simultaneously reduces the activity of lysosomes and thereby inhibits autophaortality for cardiovascular disease (54). Hypertrophy has
een considered maladaptive, and can be targeted by inter-
entions to protect against further adverse remodeling
hich would set the stage for eventual heart failure (55).
Cardiomyocyte hypertrophy can be considered a conse-
uence of a shift in the balance between atrophy and
ypertrophy signaling (56). The currently known prohyper-
rophic signaling mechanisms have been reviewed with
ossible targets for interventions. Briefly, hypertrophy can
e activated by biomechanical stress in response to hemo-
ynamic load increase, G protein pathways in response to
xtracellular signaling molecules, peroxisome proliferator
ctivation in response to fatty acid oxidation, and phospho-
nositide 3-kinase in response to Akt signaling (57).
An exception where hypertrophy has no association with
oor clinical prognosis is in athletes’ hearts. Differences
etween pathological hypertrophy (in diseased or aging
earts) and physiological hypertrophy (in athletes’ hearts)
ave been recently reviewed in great depth (58). Moreover,
t is certainly possible that enlargement of cardiomyocytes
ue to pathological responses is not the sole cause of
ysfunctional hearts. For instance, the increase in protein
ynthesis in response to hypertrophic signaling in the
ontext of inefficient autophagy and cytosol awash with
xidative agents leaked from damaged mitochondria can
ead to the runaway accumulation of damaged protein that
trains the already inefficient autophagy machinery. More-
ver, an increase in the energy demands of hypertrophied
ardiomyocytes require more energy output from a pool of
, nutrient deprivation (49), or various intracellular signals. The process initiates
hich engulfs damaged proteins and organelles. Autophagosomes then fuse with
he cardiomyocyte’s need for autopahgy to maintain intracellular homeostasis,
x. Figure illustration by Craig Skaggs.n (48)
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Aging and Post-Infarct Remodeling December 28, 2010/January 4, 2011:9–17oorly performing and highly damaged mitochondria, which
an further wear down the already stressed mitochondria,
ausing cytotoxic effects such as leakage of reactive oxygen
pecies or cytochrome C release, resulting in cardiomyocyte
poptosis (Fig. 3).
enewal failure. The number of cardiomyocytes in both
he rodent and human heart declines with age (59). The
ery low rate of cell death in a normal heart, occurring in
pproximately 0.001% to 0.01% of cells at any given time
oint, as well as the availability of cardiomyocyte hypertro-
hy and fibrosis as compensatory mechanisms for cell loss in
ging hearts, were thought to reduce the requirement for
ardiomyocyte regeneration (59). Additionally, after events
uch as coronary ischemia that lead to massive loss of
ardiomyocytes, hearts are left with permanent scarring and
n irreversible decrease in function. Until recently, there was
o firm evidence to support the existence of cardiomyocyte
enewal. Now it appears there are 2 sources for renewal of the
ardiomyocyte pool: division of existing adult cardiomyocytes,
nd differentiation of precursor cells (or stem cells) into new
ardiomyocytes (60,61). Both of these processes may be
ubject to the ravages of aging.
Adult cardiomyocytes possess a limited capacity for pro-
iferation (62). The rarity of cardiomyocyte mitosis at
aseline, estimated at around 14 cells per million (63),
akes the role of cardiomyocyte renewal in aging difficult to
tudy or speculate upon using current laboratory techniques.
nterestingly, this number is within the same order of
agnitude to the apoptotic index found in a normal adult
eart (27). Assuming the time course of mitosis is similar to
poptosis (both process can be completed in the order of
ours), the mitotic and apoptotic indexes suggest a signifi-
ant contribution to cardiomyocyte renewal through cell
ivision. It is then tempting to speculate whether the
eduction of cardiomyocyte renewal with aging is a result
f reduction in cardiomyocyte mitosis. Many factors may
ead to cell cycle arrest in aging, including telomere
hortening, mutation accumulation, oxidative stress, al-
ered gene expression, and paracrine signaling, as re-
iewed by Campisi et al. (64). The overlap of these
actors with senescent cardiomyocyte phenotype may
rovide possible targets for antiaging therapy.
Stem cells or precursor cells can give rise to all the cell
ypes within the adult heart (65). Furthermore, many types
f stem or precursor cells have been used to regenerate
ardiac tissue in experimental models. These include bone
arrow–derived cells (66), mesenchymal stem cells (67),
mbilical cord blood cells (68), adipose-derived stem cells
69), endothelial progenitor cells (70), and resident cardiac
rogenitor cells (CPC) (71). It is known that stem cells,
hich are popularly considered to be the fountain of youth,
an be drained with aging. Old stem cells are associated
ith replicative senescence or stress-induced senescence,
endering the cells incapable of further division and self-
enewal (72). Replicative senescence involves the shortening
f the telomere, a repeated sequence capping the end of chromosomes. Telomeres protect the integrity of coding
equences on chromosomes from the unavoidable loss of
NA content due to the inability to synthesize DNA on the
agging strand at its very end (73). Increasing metabolic
ssaults due to aging can also induce cellular senescence by
rresting cells from entering cycle (64). It has been found
hat CPC senesce as well. Phenotypes of senescence such as
elomere shortening and accumulation of p16INK4a are
bserved in CPC from aged and diseased hearts (74), which
ay lead to a decrease in regenerative capacity.
A recent groundbreaking work to pinpoint the extent of
ardiomyocyte renewal in aging was carried out by a global
cale pulse-chase experiment. By taking advantage of the
ecade-long surge in nuclear bomb testing, which leads a
ulse that incorporates 14C in DNA, and examining the
ost-mortem 14C content in cardiomyocyte nuclei, Berg-
ann et al. were able to establish a mathematical model to
escribe cardiomyocyte renewal in the human heart (75).
heir model suggests that in young hearts, 1% of cardio-
yocytes are renewed annually. The rate decreases to 0.45%
n aging hearts. Aging cardiomyocytes, however, do not
xhibit a lower rate of cell death compared with the young
nes (31); therefore, the low cardiomyocyte turnover phe-
omenon more likely reflects the decrease in the formation
f new cells. Reduced cardiomyocyte renewal in aging may
epresent a therapeutic target in post-infarction LV remod-
ling in elderly patients.
ging of other cell types. Aging of the heart as an organ
s certainly not confined to the aging of cardiomyocytes
lone. Although cardiomyocytes make up most of the mass
f the heart, numerically they constitute only one-half of the
ell population. Cardiac fibroblasts, endothelial cells lining
apillaries, and smooth muscle cells make up most of the
emaining one-half of the cell population (76). Cardiac
broblasts are responsible for laying out the cardiac tissue
caffold through their production, maintainance, and re-
odeling of extracellular matrix (ECM). Fibroblasts from
ged hearts have impaired proliferative capacity (77) and a
lunted response to profibrotic stimuli in vitro (78). Al-
hough aged hearts have more fibrosis than young hearts at
aseline, a pathological finding, when rapid elaboration of
brous tissue is necessary, such as following MI, the aged
broblast is unable to respond adequately. Aging hearts
isplay reduced collagen deposition in the scar, delayed
tablization of scarring, and reduced but prolonged inflam-
ation (78), suggesting that cardiac fibroblasts become
ysfunctional with age. This may contribute to increased
isk of cardiac rupture following MI in the elderly. Little is
nown about the effects of age on endothelial cells and
mooth muscle cells in the post-infarction setting. Last,
ging of cardiac stem cells, which have shown to posess
ifferentiation capacity into various cardiac cell lineages
71), may contribute to the deterioration and reduction in
egeneration of nonmuscle cells in myocardium.
In addition to cellular changes with age, the ECM alsohanges. Age is associated with increased expression of
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December 28, 2010/January 4, 2011:9–17 Aging and Post-Infarct Remodelingeveral ECM proteins, including collagen, fibronectin, and
lpha 1 and alpha 5 integrin (79). Furthermore, there is
ncreased collagen cross-linkng with advanced age, which
an contribute to ventricular stiffness, and this can be
odulated with exercise (80). Just as the function of a heart
s achieved by the interactions of its various cell types,
tudying the aging heart requires consideration of the
ge-related change in ECM signaling, as well as cell–cell
nteractions.
linical Sequelae of Cellular Changes
n LV Remodeling With Age
he molecular and cellular changes described in the previ-
us text have direct effects on cardiac function, and thereby
n patient outcomes. Loss of cardiomyocytes with age
ppears to be due to 2 separate mechanisms: loss of cells due to
ear-and-tear that are not replaced (impaired cardiomyocyte
ivision and cardiac stem cell senescence) and active loss of
ells due to activation of apoptosis. In addition, cardiomyocyte
unction is impaired with age. The result is a predisposition
oward LV impairment and heart failure at baseline. Fur-
hermore, with the stress of MI, there is resultant inability
f the aged heart to cope, and post-infarction LV remod-
ling is more pronounced. This translates into the higher
linical incidence of post-infarction heart failure in elderly
atients.
Cardiac fibroblast dysfunction with age contributes to
igher baseline levels of fibrosis, which likely contributes to
iastolic heart failure in the elderly. Following MI, aged
broblasts are unable to elaborate a strong, mature infarct
car, and there is resultant infarct expansion, heart failure,
nd excess mortality, as seen in animal models and clinical
tudies described in the previous text. Table 1 summarizes
hese changes.
anagement of Elderly Patients
ith Post-Infarction LV Remodeling
uidelines from the American College of Cardiology
ACC) and American Heart Association (AHA) for man-
gement of patients with ST-segment elevation MI (81),
nd the 2009 update (82) make no distinction based on age
or the assessment and initial management of MI. All
ffects of Aging on the HeartTable 1 Effects of Aging on the Heart
Cellular and Molecular
Changes
Effect of
Aging*
Clinical
Bas
Cardiomyocyte survival 2 Impaired sy
Cardiomyocyte proliferation 2 Impaired sy
Cardiac stem cell number 2 Impaired sy
Cardiomyocyte diameter 1 LV hypertrop
Myocardial fibrosis 1 Diastolic dy
Dysfunctional fibroblasts 1 Diastolic dyDownward-pointing arrow (2) indicates a decrease in effects; upward-pointing arrow (1) indicates an i
LV  left ventricular; MI  myocardial infarction.atients with ST-segment elevation MI should undergo
apid evaluation for reperfusion therapy and have a reper-
usion strategy implemented promptly after contact with the
edical system (Level of Evidence: A). Elderly patients
ppear to have a modest benefit from PCI over fibrinolysis,
lthough the benefit is mainly in recurrent ischemia (17,83).
his suggests that suitable elderly patients can be offered
rimary PCI and may benefit from this approach. The class
f recommendation for both primary PCI and rescue PCI in
atients with cardiogenic shock is Class II in patients over
5 years of age and Class I in younger patients. This is
ainly because younger patients demonstrated clear benefit
n the SHOCK (Should We Emergently Revascularize
ccluded Coronaries for Cardiogenic Shock) trial (84),
hereas older patient data are based on registries (18,19).
hen PCI is not available and fibrinolysis is the treatment
f choice for reperfusion, elderly patients have improved
utcomes when treated with fibrinolytic agents compared
ith placebo (10), but this benefit may not extend beyond
5 years of age.
The guidelines for standard adjunctive therapies during
he index admission, such as aspirin, beta-blockers, and
ntiplatelet agents, make no differential recommendations
ased on age. However, the addition of prasugrel in the
009 update comes with a Federal Drug Administration
arning about use in those 75 years of age or older, because
f lack of benefit and increased risk of intracranial hemor-
hage in this age group (85). In addition, low molecular
eight heparin should not be used as an alternative to
nfractionated heparin in combination with fibrinolytic
herapy in patients over 75 years of age.
After reperfusion of MI, therapies to prevent and treat
V remodeling include beta-blockers, ACE inhibitors,
ldosterone antagonists, and cardiac rehabilitation. In the
CC/AHA guidelines, these are recommended for all, with
o stipulation on age. Aspirin, ACE inhibitors, beta-
lockers, and statins appear to be at least as effective in
lderly patients as in younger patients following MI (12). In
ummary, with the exception of prasugrel and low molecular
eight heparin after fibrinolysis, elderly patients should be
onsidered for the same therapies as young patients in the
etting of acute MI and for prevention of long-term adverse
V remodeling.
s at Clinical Effects
After MI
unction LV dilation, eccentric remodeling, and systolic dysfunction
unction LV dilation, eccentric remodeling, and systolic dysfunction
unction LV dilation, eccentric remodeling, and systolic dysfunction
Increased wall stress, concentric remodeling
on Fibrosis of noninfarct zone, increased arrhythmias
on Infarct expansionEffect
eline
stolic f
stolic f
stolic f
hy
sfuncti
sfunctincrease.
R
D
C
F
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
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